CD70: a new tumor specific biomarker for renal cell carcinoma
- PMID: 15879877
- DOI: 10.1097/01.ju.0000158121.49085.ba
CD70: a new tumor specific biomarker for renal cell carcinoma
Abstract
Purpose: To date there have been no specific tumor markers available for the differential diagnosis of renal cell carcinoma (RCC). In an earlier study we identified high RNA expression of CD70 in clear cell RCC. CD70 is a type II transmembrane protein belonging to the tumor necrosis factor family. It represents the ligand for CD27, a glycosylated transmembrane protein of the tumor necrosis factor receptor family. To our knowledge the function of CD70 in solid tumors is not known. In the current study we analyzed CD70 protein expression in different RCC subtypes.
Materials and methods: A total of 68 tumor samples of different histopathological subtypes were investigated by immunochemistry, including 41 clear cell, 19 papillary and 5 chromophobe RCCs, and 3 oncocytomas as well as their normal tissue counterparts. Immunochemistry was performed on frozen tissue samples using monoclonal antibody against CD70.
Results: None of the normal kidney tissues showed CD70 expression. In contrast, all clear cell RCCs expressed CD70 at a high level. Positive immunostaining was observed in 1 papillary (5%) and in 1 chromophobe (20%) RCC. Five papillary tumor samples (26%) showed focal staining in less than 5% of cells. All other samples were negative for CD70.
Conclusions: Our study identified CD70 as a new specific tumor marker for clear cell RCC. This new marker can be used for differential diagnosis in cases of uncertain histological classification. The function of this protein in tumorigenesis and its use as a diagnostic marker in serum and urine or as a therapeutic tool must be investigated in further studies.
Comment in
-
Tumor markers for renal cell carcinoma.J Urol. 2005 Jun;173(6):1847. doi: 10.1097/01.ju.0000163779.65884.6c. J Urol. 2005. PMID: 15879760 No abstract available.
Similar articles
-
Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.J Urol. 2009 May;181(5):2305-11. doi: 10.1016/j.juro.2009.01.003. Epub 2009 Mar 19. J Urol. 2009. PMID: 19303095
-
Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.Am J Surg Pathol. 2007 Oct;31(10):1528-33. doi: 10.1097/PAS.0b013e318058818c. Am J Surg Pathol. 2007. PMID: 17895753
-
Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry.Eur J Cancer. 2005 Aug;41(12):1794-801. doi: 10.1016/j.ejca.2005.05.005. Eur J Cancer. 2005. PMID: 16043348
-
Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.Cancer Biomark. 2010;7(6):261-8. doi: 10.3233/CBM-2010-0195. Cancer Biomark. 2010. PMID: 21694464 Review.
-
The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.Clin Lab Med. 2005 Jun;25(2):247-57. doi: 10.1016/j.cll.2005.01.004. Clin Lab Med. 2005. PMID: 15848735 Review.
Cited by
-
Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer.Cancers (Basel). 2024 May 6;16(9):1787. doi: 10.3390/cancers16091787. Cancers (Basel). 2024. PMID: 38730739 Free PMC article.
-
Immunoinformatics Approach to Design a Chimeric CD70-Peptide Vaccine against Renal Cell Carcinoma.J Immunol Res. 2024 Jan 27;2024:2875635. doi: 10.1155/2024/2875635. eCollection 2024. J Immunol Res. 2024. PMID: 38314087 Free PMC article.
-
The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.Front Oncol. 2023 Oct 2;13:1240061. doi: 10.3389/fonc.2023.1240061. eCollection 2023. Front Oncol. 2023. PMID: 37849799 Free PMC article.
-
Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.J Pers Med. 2023 Aug 30;13(9):1339. doi: 10.3390/jpm13091339. J Pers Med. 2023. PMID: 37763107 Free PMC article. Review.
-
Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.Oncologist. 2023 Apr 6;28(4):297-308. doi: 10.1093/oncolo/oyac263. Oncologist. 2023. PMID: 36745503 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials